I-Semaglutide VS Tirzepatide

I-Semaglutide ne-Tirzepatide imithi emibili emisha esekwe ku-GLP-1 esetshenziselwa ukwelapha uhlobo lwesifo sikashukela sohlobo lwe-2 nokukhuluphala.
I-Semaglutide ibonise imiphumela ephakeme ekunciphiseni amazinga e-HbA1c nokukhuthaza ukulahlekelwa isisindo. I-Tirzepatide, inoveli ekabili ye-GIP/GLP-1 receptor agonist, nayo igunyazwe yi-US FDA kanye ne-European EMA ekwelapheni isifo sikashukela sohlobo 2.

Ukusebenza kahle
Kokubili i-semaglutide ne-tirzepatide inganciphisa kakhulu amazinga e-HbA1c ezigulini ezinesifo sikashukela sohlobo 2, ngaleyo ndlela kuthuthukiswe ukulawulwa kweglucose yegazi.

Ngokuphathelene nokulahlekelwa kwesisindo, i-tirzepatide ngokuvamile ibonisa imiphumela engcono uma iqhathaniswa ne-semaglutide.

Ingozi yenhliziyo
I-Semaglutide ibonise izinzuzo zenhliziyo nemithambo yegazi esivivinyweni se-SUSTAIN-6, okubandakanya izingozi ezincishisiwe zokufa kwenhliziyo, i-myocardial infarction engabulali, kanye ne-stroke engabulali.

Imiphumela ye-Tirzepatide yenhliziyo nemithambo yegazi idinga ucwaningo olwengeziwe, ikakhulukazi imiphumela evela ocwaningweni lwe-SURPASS-CVOT.

Ukugunyazwa Kwezidakamizwa
I-Semaglutide ivunyelwe njenge-adjunct yokudla nokuzivocavoca ukuthuthukisa ukulawula ushukela wegazi kubantu abadala abanesifo sikashukela sohlobo lwe-2, nokunciphisa ingozi yezenzakalo ezinkulu zenhliziyo kubantu abadala abanesifo sikashukela sohlobo lwe-2 kanye nesifo senhliziyo esisungulwe.

I-Tirzepatide ivunyelwe njengesengezo sokudla okunekhalori encishisiwe kanye nomsebenzi okhulisiwe womzimba wokulawulwa kwesisindo esingapheli kubantu abadala abanokukhuluphala ngokweqile noma ukukhuluphala ngokweqile kanye okungenani ne-comorbidity eyodwa ehlobene nesisindo.

Ukuphatha
Kokubili i-semaglutide ne-tirzepatide zivame ukulawulwa ngomjovo ongaphansi kwesikhumba.
I-Semaglutide nayo inokwakheka komlomo okutholakalayo.